NCT07537049 2026-04-17
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
Clinical Trials
22 trialsNCT07221032 2026-04-14
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07200089 2026-04-07
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07490613 2026-03-24
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07477587 2026-03-17
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07407010 2026-02-12
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07400744 2026-02-10
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07255898 2025-12-01
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06698744 2025-09-23
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07113496 2025-08-13
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Not yet recruiting
NCT07114432 2025-08-11
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Not yet recruiting
NCT05976555 2025-06-11
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT06913179 2025-04-06
CAR-T-allo
Xuzhou Medical University
Phase 1 Not yet recruiting
NCT06913192 2025-04-06
AUTO-CAR-T
Xuzhou Medical University
Phase 1 Not yet recruiting
NCT06705725 2024-11-26
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
Carbiogene Therapeutics Co. Ltd.
Phase 1 Not yet recruiting
NCT06655519 2024-10-23
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Peking University People's Hospital
Phase 1 Not yet recruiting
NCT06500507 2024-07-15
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05498545 2022-08-12
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 1 Not yet recruiting
NCT05181501 2022-01-06
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Not yet recruiting